Markets
Business
Investing
Tech
Politics
CNBC TV
Watchlist

stocks Mylan NV

  • Mylan Results Hurt by Write-offs From Matrix Acquisition

    Mylan Laboratories reported a loss for its fiscal fourth quarter, reversing a year-ago profit, as hefty writeoffs for costs related to its acquisition of India's Matrix Labs offset strong revenue growth.

  • Stocks Close Mixed Ahead of Key Inflation Data

    Stocks ended mixed on Monday as the latest batch of merger news failed to spark excitement among investors ahead of the release of key economic data. "The market has somewhat become like Pavlov's dog, waiting for some blockbuster merger deals to be announced," said Robert Pavlik, chief investment officer at Oaktree Asset Management.

  • Hot Stocks: Nokia, Viasys Among Big Movers

    M&A news and quarterly updates provided some of the catalysts behind the most actively traded stocks on Monday.

  • Mylan to Buy Generic Drug Business from Germany's Merck

    German drug maker Merck announced that it is selling its generic drug business to Mylan Laboratories  for $6.6 billion.

  • CNBC's Domm: Today's Agenda in the Markets

    Stocks are looking for direction amid a flurry of takeover headlines this morning. Asian stocks were higher overnight on the back of Wall Street's Friday gains, but European markets are mostly weaker.

  • Generics Unit of Germany's Merck Gets Four Final Bids

    Merck, Germany's drugs and chemicals group, received four final bids for its generics drugs business, sources familiar with the situation said on Monday.

  • U.S. Regulators OK Generic Version Of Ambien Sleeping Pill

    Mylan Laboratories spacer said U.S. regulators approved its generic version of Sanofi-Aventis' sleeping pill, Ambien, in the 5 mg and 10 mg strengths.

  • Mylan Shares Rise on Improved Earnings Guidance

    Mylan Laboratories raised its fiscal 2007 earnings forecast, citing the strong performance of its generic drugs business, pushing its shares up as much as 4%.

  • Ranbaxy Out of Merck KGaA Generic Hunt; Torrent In?

    Ranbaxy Laboratories is no longer in the running to buy the generic drug business of Germany's Merck, India's CNBC TV18 reported Tuesday. Ranbaxy withdrew from the second round of bidding for the business, the television station said.

  • graphic_fast_fire.jpg
    Good Pix Gone Bad

    On February 26th, Guy Adami, The Negotiator recommended this drug play. "Mylan Labs, you've gotta go the generic route… I'm going the generic route…I like Mylan Labs here. They had a nice earnings release I think this is a stock you have to own” Well guess what...

  • Mylan CEO: We're World Leader in Generic Drugs

    More than $18 billion in pharmaceutical drugs are scheduled to go off-patent this year, and consequently medication makers are getting lots of attention from Wall Street. One company expected to benefit from patent expiration is generic drug manufacturer Mylan Labs. CNBC's Mike Huckman caught up with CEO Robert Coury at the JPMorgan Healthcare Conference in San Francisco.

  • Big Day For Apple And Earnings Season Begins

    Stocks in the U.S. are positioned to move higher on the opening after yesterday's afternoon turnaround. European stock markets are higher, and Asia turned in a mixed performance. Today kicks off the fourth quarter earnings season with the release of Dow component Alcoa's earnings after the bell. OIL DIP: Oil is weaker again this morning and heading close to the $55 technical level traders are watching.

  • Healthcare on the Other Hill

    While on Capitol Hill the new Congress begins to take on the pharmaceuticals industry, the healthcare investment community is holding its annual confab in the hills of San Francisco--House Speaker Nancy Pelosi's home district. I'm at the 25th Annual JPMorgan Healthcare Conference at the Westin St. Francis on Union Square. The four-day event is just getting started, but the halls are...

  • CNBC'S Domm: A Real "News Feast" Next Week

    Financial markets will have plenty of news to feast on in the coming week although the markets generated enough headlines on their own in the first days of January with just a few big stories to chew on. The second week of January is quite busy. We're looking forward to some of the most important and newsy industry conferences of the year, plus the start of earnings season, an important Fed speech, and some fresh economic data.